Efavirenz Tenofovir Disoproxil Emtricitabine (Atripla) shortage status
Partial shortage
Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Efavirenz Tenofovir Disoproxil Emtricitabine products are in shortage in Canada (3 of 7 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Dec 31, 2026.
A combination of three antiviral medications used together to treat HIV infection.
Products affected
3 / 7
In shortage since
Oct 7, 2024
Est. full return
Dec 31, 2026
Reports on file
16
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
DIN 02461412 · since Oct 7, 2024, no end estimate · Disruption of the manufacture of the drug.
Active shortage
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
300MG
200MG
600MG · TABLET · TEVA CANADA LIMITED
DIN 02393549 · since Jan 20, 2025, no end estimate · Disruption of the manufacture of the drug.
Resolved
AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
300MG
200MG
600MG · TABLET · AURO PHARMA INC
DIN 02478404 · ended Dec 2, 2024 · Demand increase for the drug.
Resolved
APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
300MG
200MG
600MG · TABLET · APOTEX INC
DIN 02468247 · ended Sep 5, 2024 · Disruption of the manufacture of the drug.
Resolved
AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
300MG
200MG
600MG · TABLET · AURO PHARMA INC
DIN 02478404 · ended Nov 1, 2023 · Demand increase for the drug.
Resolved
APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
300MG
200MG
600MG · TABLET · APOTEX INC
DIN 02468247 · ended Jul 4, 2023 · Disruption of the manufacture of the drug.
Resolved
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
300MG
200MG
600MG · TABLET · TEVA CANADA LIMITED
DIN 02393549 · ended Feb 10, 2023 · Disruption of the manufacture of the drug.
Resolved
PMS-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
600MG
300MG
200MG · TABLET · PHARMASCIENCE INC
DIN 02487284 · ended Oct 21, 2022 · Disruption of the manufacture of the drug.
Discontinued
ATRIPLA
300MG
200MG
600MG · TABLET · GILEAD SCIENCES, LLC
DIN 02300699
Resolved
AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
600MG
200MG
300MG · TABLET · AURO PHARMA INC
DIN 02478404 · ended May 25, 2021 · Demand increase for the drug.
Avoided
AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
600MG
200MG
300MG · TABLET · AURO PHARMA INC
DIN 02478404 · ended Mar 26, 2020 · Demand increase for the drug.
Showing 12 of 16 reports. All reports are on file with Health Canada.
What's happening
Efavirenz Tenofovir Disoproxil Emtricitabine is currently affected by 3 active shortage reports filed with Health Canada by JAMP PHARMA CORPORATION, MYLAN PHARMACEUTICALS ULC, TEVA CANADA LIMITED.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Efavirenz Tenofovir Disoproxil Emtricitabine is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AR).
Recent changes
No changes recorded yet.
Common questions
What is Efavirenz Tenofovir Disoproxil Emtricitabine used for?
A combination of three antiviral medications used together to treat HIV infection.
When will Efavirenz Tenofovir Disoproxil Emtricitabine be back in stock in Canada?
The latest manufacturer estimate is Dec 31, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Efavirenz Tenofovir Disoproxil Emtricitabine in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.